Prestige Consumer Healthcare trades at a forward P/E of 9.3x with analyst upside of 25% and strong operating margins of 17%, but has missed earnings estimates in all 4 of the last 4 quarters with estimates trending downward — making the value case dependent on a fundamental turnaround that has not yet materialized.
Thesis pillars
- Valuation Discount Vs Quality↓Deteriorating
- Margin Quality Floor Support→Stable
- Earnings Miss Streak Resolution→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed May 14, 2026· older than 90 days
Prestige Consumer Healthcare In (PBH) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $53.28, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Leverage penalty (D/E 1.1): -0.5.
Prestige Consumer Healthcare markets OTC health and personal care brands—including Monistat, Dramamine, Clear Eyes, and Fleet—across North America (83.9% of fiscal 2026 revenues) and internationally. Walmart (~20%) and Amazon (~15%) were the only customers exceeding 10% of... Read more
Sell if holding. At $53.28, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Leverage penalty (D/E 1.1): -0.5. Chart setup: Death cross but MACD improving, RSI 65. Score 5.5/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated Nov 5, 2026Recent Developments — Prestige Consumer Healthcare In
Latest news
- NEWS Prestige Consumer Lowers FY2027 Adj EPS Guidance from $4.55-$4.65 to $4.48-$4.55 vs $4.58 Est; Lowers FY2027 Sales Guida — benzinga Nov 5, 2026 negative
- NEWS Earnings Preview: PBH to Report Financial Results Pre-market on November 05 - Moomoo — Moomoo Oct 31, 2026 neutral
- NEWS PBH Q2'26 Earnings: revenue estimate is 329.15M USD - TradingView — TradingView Oct 29, 2026 neutral
- NEWS Earnings Flash (PBH) Prestige Consumer Healthcare Inc. Posts Q1 Adjusted EPS $0.98 per Share, vs. FactSet Est of $0.88 - — marketscreener.com Aug 6, 2026 positive
- NEWS Prestige Consumer Healthcare in spotlight as earnings test acquisitions By Investing.com - Investing.com Nigeria — Investing.com Nigeria Aug 5, 2026 neutral
Latest item Nov 5, 2026 · Generated 2026-11-05T11:54:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomerWalmart20%10-K Item 1: 'Walmart accounted for approximately 20%, 19% and 20%, respectively, of our gross revenues'
- LOWCustomerAmazon15%10-K Item 1: 'Amazon accounted for approximately 15%, 14%, and 11%, respectively, of our gross revenues'
- LOWSupplierprivately owned pharmaceutical manufacturer21%10-K Item 1A: 'a privately owned pharmaceutical manufacturer...This manufacturer accounted for approximately 21%, respectively, of our gross revenues in 2026 and 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $53.28, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Consecutive earnings misses (3); Leverage penalty (D/E 1.1): -0.5. Chart setup: Death cross but MACD improving, RSI 65. Prior stop was $50.04. Score 5.5/10, moderate confidence.
Analyst target: $58.99 (+10.7% upside). Prior stop was $50.04. Stop-loss: $50.04.
Leverage penalty (D/E 1.1): -0.5; Consecutive earnings misses (3); Weak growth.
Prestige Consumer Healthcare In trades at a P/E of 14.9 (forward 10.4). TrendMatrix value score: 6.7/10. Verdict: Sell.
10 analysts rate PBH, with a consensus score of 4.0/5. 5 analysts publish price targets averaging $68.
What does Prestige Consumer Healthcare In do?Prestige Consumer Healthcare markets OTC health and personal care brands—including Monistat, Dramamine, Clear Eyes, and...
Prestige Consumer Healthcare markets OTC health and personal care brands—including Monistat, Dramamine, Clear Eyes, and Fleet—across North America (83.9% of fiscal 2026 revenues) and internationally. Walmart (~20%) and Amazon (~15%) were the only customers exceeding 10% of fiscal 2026 gross revenues. The company outsources most manufacturing to 95 third-party contractors while operating three owned facilities in the U.S., Canada, and Australia.